Prevention of cancer and inflammation by soybean protease inhibitors

Frontiers in Bioscience - Elite

Volumn 5 E, Issue 3, 2013, Pages 966-973

  Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bowman birk inhibitor; Cancer; Inflammation; Kunitz Trypsin inhibitor; Nutraceuticals; Review; Soybean

Indexed keywords

APROTININ; BACTERIUM LIPOPOLYSACCHARIDE; BOWMAN BIRK INHIBITOR; CISPLATIN; GENTAMICIN; PHOSPHATIDYLINOSITOL 3 KINASE; SOYBEAN PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL KILLING; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN MCF 7; CEREBROVASCULAR ACCIDENT; COSMIC RADIATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DENGUE; DEVELOPED COUNTRY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DNA DAMAGE; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; ISCHEMIC HEART DISEASE; LEUKOPLAKIA; LUNG CANCER; MENOPAUSAL SYNDROME; MOUTH CAVITY; MUSCLE ATROPHY; NEPHROTOXICITY; NEUTROPHIL; NONHUMAN; OBESITY; OSTEOLYSIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; SEXUAL FUNCTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DEFECT; SOYBEAN; THERAPY EFFECT; TUMOR VOLUME; UPREGULATION; UTERINE CERVIX CANCER;

GLYCINE MAX;

EID: 84884332899     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e676     Document Type: Article

References (55)

1. EG de Mejia, T Bradford, C Hasler: The anticarcinogenic potential of soybean lectin and lunasin. Nutr Rev 61, 239-46 (2003)
2. I Csaky, S Fekete: Soybean: feed quality and safety. Part 1: biologically active components. A review. Acta Vet Hung 52, 299-313 (2004)
3. M Friedman, DL Brandon: Nutritional and health benefits of soy proteins. J Agric Food Chem 49, 1069-1086 (2001)
4. I Flight, P Clifton: Cereal grains and legumes in the prevention of coronary heart disease and stroke: a review of the literature. Eur J Clin Nutr 60, 1145-1159 (2006)
5. AR Kennedy: The evidence for soybean products as cancer preventive agents. J Nutr 125, 733S-743S (1995)
6. HP Lee, L Gourley, SW Duffy, J Esteve, J Lee, NE Day: Dietary effects on breast-cancer risk in Singapore. Lancet 337, 1197-1200 (1991).
7. S Barnes, C Grubbs, KD Setchell, J Carlson: Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res 347, 239-253 (1990)
8. D Divisi, S Di Tommaso, S Salvemini, M Garramone, R Crisci: Diet and cancer. Acta Biomed Ateneo Parmense 77, 118-123 (2006)
9. S Quirce, M Fernandez-Nieto, F Polo, J Sastre: Soybean trypsin inhibitor is an occupational inhalant allergen. J Allergy Clin Immunol 109, 178 (2002)
10. M Deshimaru, R Hanamoto, C Kusano, S Yoshimi, S Terada: Purification and characterization of proteinase inhibitors from wild soja (Glycine soja) seeds. Biosci Biotechnol Biochem 66, 1897-1903 (2002)
11. AR Kennedy: Prevention of carcinogenesis by protease inhibitors. Cancer Res 54, 1999s-2005s (1994)
12. Y Birk: The Bowman-Birk inhibitor. Trypsin-And chymotrypsin-inhibitor from soybeans. Int J Pept Protein Res 25, 113-131 (1985)
13. CW Kennedy, JJ Donahue, XS Wan: Effects of the Bowman-Birk protease inhibitor on survival of fibroblasts and cancer cells exposed to radiation and cis-platinum. Nutr Cancer 26, 209-217 (1996)
14. XS Wan, TC Hamilton, JH Ware, JJ Donahue, AR Kennedy: Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells. Nutr Cancer 31, 8-17 (1998)
15. L Zhang, XS Wan, JJ Donahue, JH Ware, AR Kennedy: Effects of the Bowman-Birk inhibitor on clonogenic survival and cisplatin-or radiation-induced cytotoxicity in human breast, cervical, and head and neck cancer cells. Nutr Cancer 33, 165-173 (1999)
16. KH Dittmann, N Gueven, C Mayer, HP Rodemann: Characterization of the amino acids essential for the photoand radioprotective effects of a Bowman-Birk protease inhibitor-derived nonapeptide. Protein Eng 14, 157-160 (2001)
17. AR Kennedy, XS Wan: Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 50, 125-133 (2002)
18. PC Billings, PM Newberne, AR Kennedy: Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 11, 1083-1086 (1990)
19. AR Kennedy, Y Beazer-Barclay, KW Kinzler, PM Newberne: Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res 56, 679-682 (1996)
20. AR Kennedy, PC Billings, XS Wan, PM Newberne: Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr Cancer 43, 174-186 (2002)
21. AR Kennedy, PC Billings, PA Maki, P Newberne: Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. Nutr Cancer 19, 191-200 (1993)
22. XS Wan, JH Ware, L Zhang, PM Newberne, SM Evans, LC Clark, AR Kennedy: Treatment with soybean-derived Bowman Birk inhibitor increases serum prostate-specific antigen concentration while suppressing growth of human prostate cancer xenografts in nude mice. Prostate 41, 243-252 (1999)
23. H Witschi, I Espiritu: Development of tobacco smokeinduced lung tumors in mice fed Bowman-Birk protease inhibitor concentrate (BBIC). Cancer Lett 183, 141-146 (2002)
24. MT Huang, JG Xie, CB Lin, M Kizoulis, M Seiberg, S Shapiro, AH Conney. Inhibitory effect of topical applications of nondenatured soymilk on the formation and growth of UVB-induced skin tumors. Oncol Res 14, 387-397 (2004)
25. W. D. Johnson, L. Dooley, R. L. Morrissey, L. Arp, I. Kapetanovic, J. A. Crowell, D. L. McCormick. Oncogenicity evaluations of chemopreventive soy components in p53((+/-)) (p53 knockout) mice. Int J Toxicol. 25, 219-228 (2006)
26. R. S. Doppalapudi, E. S. Riccio, L. L. Rausch, J. A. Shimon, P. S. Lee, K. E. Mortelmans, I. M. Kapetanovic, J. A. Crowell, J. C. Mirsalis. Evaluation of chemopreventive agents for genotoxic activity. Mutat Res 629, 148-160 (2007)
27. AR Kennedy: The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68, 1406S-1412S (1998)
28. XS Wan, FL Jr Meyskens, WB Armstrong, TH Taylor, AR Kennedy: Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Cancer Epidemiol Biomarkers Prev 8, 601-608 (1999)
29. WB Armstrong, AR Kennedy, XS Wan, J Atiba, CE McLaren, FL Jr Meyskens: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9, 43-47 (2000)
30. WB Armstrong, AR Kennedy, XS Wan, TH Taylor, QA Nguyen, J Jensen, W Thompson, W Lagerberg, FL Jr Meyskens: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6, 4684-4691 (2000)
31. AW Tolcher, A Kennedy, RJ Padley, N Majeed, M Pollak, PW Kantoff: Other novel agents: Rationale and current status as chemopreventive agents. Urol 57, 86-89 (2001)
32. MA Moral, VK Khurdayan, J Bozzo: Chronicles in drug discovery. Drug News Perspect 19, 485-489 (2006)
33. Y Birk: Protein proteinase inhibitors in legume seeds-overview. Arch Latinoam Nutr 44, 26S-30S (1996)
34. JH Ware, XS Wan, AR Kennedy: Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells. Nutr Cancer 33, 174-177 (1999)
35. HMK Murthy, K Judge, L DeLucas, R Padmanabhan: Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: Implications for flaviviral polyprotein processing and drug design. J Mol Biol 301, 759-767 (2000). 36. AR Kennedy, Z Zhou, JJ Donahue, JH Ware: Protection against adverse biological effects induced by space radiation by the Bowman-Birk inhibitor and antioxidants. Radiat Res 166, 327-332 (2006)
36. KH Dittmann, C Mayer, HP Rodemann: Radioprotection of normal tissue to improve radiotherapy: the effect of the Bowman Birk protease inhibitor. Curr Med Chem Anticancer Agents 3, 360-363 (2003)
37. CA Morris, LD Morris, AR Kennedy, HL Sweeney: Attenuation of skeletal muscle atrophy via protease inhibition. J Appl Physiol 99, 1719-1727 (2005)
38. SB Malkowicz, SP Liu, GA Broderick, AJ Wein, AR Kennedy, RM Levin: Effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity. Neurourol Urody 22, 54-57 (2003)
39. YW Chen, SC Huang, SY Lin-Shiau, JK Lin: Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 26, 1296-1306 (2005)
40. DL Brandon, M Friedman: Immunoassays of soy proteins. J Agric Food Chem 50, 6635-6642 (2002)
41. FL Meyskens: Development of Bowman-Birk inhibitor for chemoprevention of oral head and neck cancer. Ann N Y Acad Sci 952, 116-123 (2001)
42. AR Kennedy: Chemopreventive agents: protease inhibitors. Pharmacol Ther 78, 167-209 (1998)
43. A Clemente, JM Gee, IT Johnson, DA Mackenzie, C Domoney: Pea (Pisum sativum L. ) protease inhibitors from the Bowman-Birk class influence the growth of human colorectal adenocarcinoma HT29 cells in vitro. J Agric Food Chem 53, 8979-8986 (2005)
44. WB Armstrong, XS Wan, AR Kennedy, TH Taylor, FL Jr. Meyskens: Development of the Bowman-Birk inhibitor for oral cancer chemoprevention and analysis of Neu immunohistochemical staining intensity with Bowman-Birk inhibitor concentrate treatment. Laryngoscope 113, 1687-1702 (2003)
45. K Suzuki, T Yano, Y Sadzuka, T Sugiyama, T Seki, R Asano: Restoration of connexin 43 by Bowman-Birk protease inhibitor in M5076 bearing mice. Oncol Rep 13, 1247-1250 (2005)
46. Y Yamasaki, S Satomi, N Murai, S Tsuzuki, T Fushiki: Inhibition of membrane-Type serine protease 1/matriptase by natural and synthetic protease inhibitors. J Nutr Sci Vitaminol (Tokyo) 49, 27-32 (2003)
47. F Syeda, J Grosjean, RA Houliston, RJ Keogh, TD Carter, E Paleolog, CP Wheeler-Jones: Cyclooxygenase-2 induction and prostacyclin release by protease-Activated receptors in endothelial cells require cooperation between mitogen-Activated protein kinase and NF-kappaB pathways. J Biol Chem 281, 11792-11804 (2006)
48. KD Jofuku, RD Schipper, RB Goldberg: A frameshift mutation prevents Kunitz trypsin inhibitor mRNA accumulation in soybean embryos. Plant Cell 1, 427-435 (1989)
49. H Kobayashi, Y Fukuda, R Yoshida, Y Kanada, S Nishiyama, M Suzuki, N Kanayama, T Terao: Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model. Int J Cancer 112, 519-524 (2004)
50. K Inagaki, H Kobayashi, R Yoshida, Y Kanada, Y Fukuda, T Yagyu, T Kondo, N Kurita, T Kitanaka, Y Yamada, Y Sakamoto, M Suzuki, N Kanayama, T Terao: Suppression of urokinase expression and invasion by a soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-dependent signaling pathways. J Biol Chem 280, 31428-31437 (2005)
51. H Kobayashi, M Suzuki, N Kanayama, T Terao: A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation. Clin Exp Metastasis 21, 159-166 (2004)
52. H Kobayashi, R Yoshida, Y Kanada, Y Fukuda, T Yagyu, K Inagaki, T Kondo, N Kurita, M Suzuki, N Kanayama, T Terao: Dietary supplementation of soybean kunitz trypsin inhibitor reduces lipopolysaccharide-induced lethality in mouse model. Shock 23, 441-447 (2005)
53. H Kobayashi, R Yoshida, Y Kanada, Y Fukuda, T Yagyu, K Inagaki, T Kondo, N Kurita, Y Yamada, T Sado, T Kitanaka, M Suzuki, N Kanayama, T Terao: A soybean Kunitz trypsin inhibitor reduces tumor necrosis factor-Alpha production in ultraviolet-exposed primary human keratinocytes. Exp Dermatol 14, 765-774 (2005)
54. H Kobayashi, R Yoshida, Y Kanada, Y Fukuda, T Yagyu, K Inagaki, T Kondo, N Kurita, M Suzuki, N Kanayama, T Terao: Suppression of lipopolysaccharideinduced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor. J Periodontal Res 40, 461-468 (2005)
55. 2+ influx through L-Type voltagegated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagonlike peptide-1 in pancreatic beta-cells. J Biol Chem 277, 48146-48151 (2002)